Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
Director comp.
Acq. announced
Director departure
|
|
RHYTHM PHARMACEUTICALS, INC. (RYTM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Other Events Interactive Data |
| 08/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/01/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Three months ended March 31, 2023 2022 Revenues: Product revenue, net $ 11,469 $ 1,498 Costs and expenses: Cost of sales 1,421 230 Research and development 37,945 32,510 Selling, general, and administrative 24,634 21,449 Total costs and expenses 64,000 54,189 Loss from operations Other income: Other expense, net Interest expense — Interest income 3,440 160 Total other income , net 352 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 56,708,975 50,326,627 Other comprehensive loss: Net loss $ $ Foreign currency translation adjustment 21 — Unrealized gain , net on marketable securities 65 Comprehensive loss $ $ Condensed Consolidated Balance Sheets" |
|
| 03/01/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Investor presentation |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/15/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/02/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 04/06/2022 |
8-K
| Investor presentation |
| 03/01/2022 |
8-K
| Quarterly results |
| 12/08/2021 |
8-K
| Quarterly results |
| 11/02/2021 |
8-K
| Quarterly results |
| 09/02/2021 |
8-K
| Quarterly results |
| 08/03/2021 |
8-K
| Quarterly results |
| 06/14/2021 |
8-K
| Quarterly results |
| 05/03/2021 |
8-K
| Quarterly results |
| 04/23/2021 |
8-K
| Quarterly results |
| 03/16/2021 |
8-K
| Quarterly results |
| 03/01/2021 |
8-K
| Quarterly results |
| 02/05/2021 |
8-K
| Quarterly results |
| 02/03/2021 |
8-K
| Quarterly results |
| 02/02/2021 |
8-K
| Quarterly results |
| 01/05/2021 |
8-K
| Quarterly results |
| 01/04/2021 |
8-K/A
| Quarterly results |
| 12/11/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/02/2020 |
8-K
| Quarterly results|
Docs:
|
"Rhythm Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Operating expenses: Research and development $ 22,995 $ 26,572 $ 68,496 $ 84,641 Selling, general, and administrative 11,289 10,535 33,006 27,135 Total operating expenses 34,284 37,107 101,502 111,776 Loss from operations Other income : Interest income, net 466 1,104 2,403 4,003 Total other income, net 466 1,104 2,403 4,003 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average common shares outstanding, basic and diluted 44,142,334 34,541,765 44,097,178 34,470,995 Other comprehensive loss: Net loss $ $ $ $ Unrealized gain on marketable securities — 238 — Comprehensive loss $ $ $ ..." |
|
| 09/16/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/03/2020 |
8-K
| Quarterly results |
|
|
|